Evaluation in nonhuman primates of vaccines against Ebola virus.
about
Animal models for Ebola and Marburg virus infectionsVesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primatesHuman fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosisCurrent ebola vaccinesMucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responsesDevelopment of a new vaccine for the prevention of Lassa fever.Ebola haemorrhagic feverAlphavirus replicon particles containing the gene for HER2/neu inhibit breast cancer growth and tumorigenesis.Pre-symptomatic diagnosis and treatment of filovirus diseasesEbola virus vaccines: an overview of current approachesMouse models for filovirus infectionsVaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus InfectionsPreparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught UsGlobal research trends of World Health Organization's top eight emerging pathogens.Progress of vaccine and drug development for Ebola preparednessEbola hemorrhagic Fever and the current state of vaccine developmentProgress towards the treatment of Ebola haemorrhagic fever.Ebola and Marburg virus vaccines.[Overview of the Ebola vaccines in pre-clinical and clinical development].A small nonhuman primate model for filovirus-induced diseaseEstablishment and characterization of a lethal mouse model for the Angola strain of Marburg virusMucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.Ebola Vaccine: How Far are we?High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona.Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.Ebola virus pathogenesis: implications for vaccines and therapies.Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.Are we any closer to combating Ebola infections?A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challengeVaccines. An Ebola whole-virus vaccine is protective in nonhuman primatesVesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy.Ebola virus-like particles protect from lethal Ebola virus infection.Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies.Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicineAlphavirus vectors for vaccine production and gene therapy.Advances in virus-like particle vaccines for filoviruses.Defensive applications of gene transfer technology in the face of bioterrorism: DNA-based vaccines and immune targeting.Hegemonic structure of basic, clinical and patented knowledge on Ebola research: a US army reductionist initiative.
P2860
Q21131118-CA34A183-4A52-4837-AB8B-CFF9D852AE6CQ21131585-EB3B3BBC-936F-4D05-8F04-B29E60F0C684Q21144780-E6E6D59D-094B-48BE-A762-599F92698551Q21534720-A43F5D55-E16F-4E29-A36E-4B3922AB8797Q21562420-D54EA563-106C-46DD-9B81-0D880F1F7C67Q21563440-B8636EAB-B275-43CA-AD76-0249A568BDF4Q24629338-923F2295-163F-4959-8696-20C9118490D3Q24796792-44E1022E-C4A1-4614-BDFF-1486B86879D1Q26823831-E6DA3526-DE8F-4BEC-8451-A907F3E1D5B9Q26999232-310E3072-1A04-47BB-BD84-B33A7C49B4BFQ27011569-FF7A1449-B8C5-4AF7-9762-4975A02B8DF0Q27485491-61D289F2-D571-4EBC-B9BE-800302676809Q28397866-0FEC100A-A830-453B-9E88-28B21CBFA0B8Q30151375-FCF76C1B-FBEC-4E37-9217-3E585E66789EQ30204870-B7E67645-F520-4DD7-9851-177802FF586BQ30205198-CC1F15EF-3493-40E3-8CE5-D88EC44D8DDBQ30230272-B2A68199-A0BA-4B60-9AC4-9AD618A30445Q30234637-0E348665-97A2-4864-A5CC-E697C080E035Q30245207-DEB52CCD-B8BA-48F4-BEB8-4F5A30FD9B86Q33397400-26369EA9-0591-40A8-99C9-32921863C4C1Q33417197-44E27C19-EB7E-425D-BE1C-D6DBA79806A0Q33743800-2B1C1EFA-35F6-463B-BAF6-7E2C911D5190Q33831877-187FC2B5-93BD-4D83-8EEC-8550B5FEC5F1Q33919019-C275B465-5626-46BF-BF18-8FD84DA64AA4Q33920185-2C3C9597-D690-444F-AC6F-69063BDAF2B9Q33967985-A275F342-A593-497A-89BF-E47B1D98FC7AQ33987611-1ED8FC3D-EA40-415B-8BB2-1459EFC535DFQ34022601-FA4D279C-C0E8-4FD8-A131-DADC0565F2B6Q34029668-7ADE0929-99B5-4761-82E8-D7B26DC51FF0Q34317031-F5964A47-14C6-4E8D-B6CB-DBC8BC76DE58Q34434713-0E33E223-D9CA-4BF2-A8FA-71C97FB50227Q34468847-B333B313-87D7-46D6-B3CE-33E2D72CF838Q34632946-CB4EBE78-9124-490A-A7F6-10EED80FB942Q34792924-25F52B41-3777-480D-8542-D1C7F050EA09Q34971349-F4A94B2A-BBCC-40E4-99A9-8B2087A3C8B2Q35048254-A9D4EB89-15D0-4938-9909-AEC96D3F8104Q35194202-10A107F2-9016-426B-999E-898BDD311285Q35300029-A3C02224-EF05-435E-A07B-C4F58FA910D0Q35594090-44F62C5D-EFB5-471C-90E7-555A8633EC90Q35595035-B7510355-0DE5-4131-B342-A280830ECCDF
P2860
Evaluation in nonhuman primates of vaccines against Ebola virus.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Evaluation in nonhuman primates of vaccines against Ebola virus.
@ast
Evaluation in nonhuman primates of vaccines against Ebola virus.
@en
type
label
Evaluation in nonhuman primates of vaccines against Ebola virus.
@ast
Evaluation in nonhuman primates of vaccines against Ebola virus.
@en
prefLabel
Evaluation in nonhuman primates of vaccines against Ebola virus.
@ast
Evaluation in nonhuman primates of vaccines against Ebola virus.
@en
P2093
P2860
P356
P1476
Evaluation in nonhuman primates of vaccines against Ebola virus.
@en
P2093
Jonathan Smith
Kelly J Davis
Kevin Anderson
Peter Pushko
P2860
P304
P356
10.3201/EID0805.010284
P577
2002-05-01T00:00:00Z